Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CASi-005 is a preclinical-stage small interfering RNA (siRNA) therapeutic being developed by Switch Therapeutics. It utilizes the company's proprietary Conditionally Activated siRNA (CASi) platform, which is designed for targeted delivery and activation, specifically optimized for central nervous system (CNS) applications. The CASi platform aims to provide long-lasting gene knockdown with improved safety and potency compared to traditional RNAi approaches. While the specific biological target and primary indication remain undisclosed, the program is part of a pipeline focused on addressing significant unmet needs in neurological disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CASi-005.